title: Impact of protease inhibitors on intracellular concentration of tenofovir-diphosphate among HIV-1 infected patients.
abstract: Intracellular nucleoside reverse transcriptase inhibitor (NRTI) concentrations are associated with plasma HIV-1 response. Coadministration of protease inhibitors with NRTIs can affect intracellular concentrations due to protease inhibitor inhibition of efflux transporters. Tenofovir-diphosphate (TFV-DP) concentrations within peripheral blood mononuclear cells were compared among individuals receiving either atazanavir or darunavir-based regimens. There was a trend towards higher TFV-DP concentrations among women and among participants receiving atazanavir. TFV-DP intracellular concentrations were positively associated with undetectable plasma HIV-1 RNA.
authors: aEmory University School of Medicine, Department of Medicine, Division of Infectious Diseases bCenter for AIDS Research, Emory University School of Medicine, Department of Pediatrics, Atlanta, Georgia cUniversity of Alabama-Birmingham School of Medicine, Department of Pharmacology and Toxicology, Division of Clinical Pharmacology, Birmingham, Alabama dEmory University, Rollins School of Public Health, Department of Global Health, Atlanta eAtlanta VA Medical Center, Decatur, Georgia, USA.
authors: Cecile D
authors: CD
authors: Lahiri
authors: Sijia
authors: S
authors: Tao
authors: Yong
authors: Y
authors: Jiang
authors: Anandi N
authors: AN
authors: Sheth
authors: Edward P
authors: EP
authors: Acosta
authors: Vincent C
authors: VC
authors: Marconi
authors: Wendy S
authors: WS
authors: Armstrong
authors: Raymond F
authors: RF
authors: Schinazi
authors: Aswani
authors: A
authors: Vunnava
authors: Sara
authors: S
authors: Sanford
authors: Ighovwerha
authors: I
authors: Ofotokun
mesh_terms: D000225:Adenine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000493:pharmacokinetics; D000328:Adult; D019380:Anti-HIV Agents / Q000008:administration & dosage / Q000493:pharmacokinetics*; D003430:Cross-Sectional Studies; D003600:Cytosol / Q000737:chemistry*; D004347:Drug Interactions; D005260:Female; D015658:HIV Infections / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000008:administration & dosage / Q000493:pharmacokinetics*; D006801:Humans; D007963:Leukocytes, Mononuclear / Q000737:chemistry*; D008297:Male; D008875:Middle Aged; D010755:Organophosphates / Q000008:administration & dosage / Q000493:pharmacokinetics*
chemical_list: D019380:Anti-HIV Agents; D017320:HIV Protease Inhibitors; D010755:Organophosphates; C583447:tenofovir diphosphate; D000225:Adenine